Fusion Pharmaceuticals (Fusion Pharmaceuticals) Debt-to-Equity : 0.23 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Fusion Pharmaceuticals Debt-to-Equity?

Fusion Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.16 Mil. Fusion Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $46.17 Mil. Fusion Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $222.48 Mil. Fusion Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 0.23.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Fusion Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

FUSN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.23 Max: 0.25
Current: 0.23

During the past 7 years, the highest Debt-to-Equity Ratio of Fusion Pharmaceuticals was 0.25. The lowest was 0.03. And the median was 0.23.

FUSN's Debt-to-Equity is ranked worse than
59.68% of 1069 companies
in the Biotechnology industry
Industry Median: 0.14 vs FUSN: 0.23

Fusion Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Fusion Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Pharmaceuticals Debt-to-Equity Chart

Fusion Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.03

0.25

0.23

Fusion Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.25	0.25	0.25	0.28	0.23

Competitive Comparison of Fusion Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Fusion Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fusion Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Fusion Pharmaceuticals's Debt-to-Equity falls into.

Fusion Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Fusion Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.163	+	46.168)	/	222.48
	=	0.23

Fusion Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.163	+	46.168)	/	222.48
	=	0.23

Fusion Pharmaceuticals (NAS:FUSN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Fusion Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Fusion Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusion Pharmaceuticals (Fusion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Pharmaceuticals Inc (NAS:FUSN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

270 Longwood Road South, Hamilton, ON, CAN, L8P 0A6

Website

https://www.fusionpharma.com

Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others.

Executives

Teresa Marie Bitetti	director	40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jeremy Bender	director	395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
David D. Meek	director	3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Dmitri Bobilev	officer: Chief Medical Officer	C/O FUSION PHARMACEUTICALS INC., 270 LONGWOOD RD. SOUTH, HAMILTON Z4 L8P 0A6
Steven Gannon	director	C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8
John Valliant	director, officer: Chief Executive Officer	FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON A6 L8P 0A6
Christopher P Leamon	officer: Chief Scientific Officer	C/O FUSION PHARMACEUTICALS INC., 2 INTERNATIONAL PLACE SUITE 2310, BOSTON MA 02110
Mohit Rawat	officer: President and CBO	FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P 0A6
Donald A Bergstrom	director	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Philina Lee	director	C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6
Adams Street Partners Llc	10 percent owner	ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Barbara Gayle Duncan	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
John J Crowley	officer: Chief Financial Officer	251 BALLARDVALE STREET, WILMINGTON MA 01887
Healthcap Vii, L.p.	10 percent owner	18 AVENUE D'OUCHY, CH 1006 LAUSANNE V8 1000-1018
James J O'leary	officer: Chief Medical Officer	830 WINTER STREET, WALTHAM MA 02452